Trevi Therapeutics, Inc. TRVI R2KR3KPHARMA
Company Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.19.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +65.92% |
| 6 Months: | -12.49% |
| 3 Months: | -30.41% |
| 1 Month: | -14.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.76 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 35.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRVI Trevi Therapeutics, Inc. R2KR3KPHARMA | 12.61 | -36.03 | $1.80B | 0.00% | -26.85% | -19.66% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.14M | -4.38M | -4.96M | -4.81M | -7.42M | -7.65M | -8.64M | -7.41M | -7.24M | -8.09M | -9.17M | -6.95M | -7.03M | -7.82M | -8.40M | -7.56M | -8.38M | -9.04M | -11.91M | -13.29M | -14.09M | -11.47M | -13.72M | -13.92M | -14.91M | -20.51M |
| Net Income | -4.05M | -4.86M | -5.65M | -4.80M | -7.35M | -7.37M | -8.47M | -7.38M | -7.38M | -8.37M | -9.79M | -7.25M | -7.33M | -8.05M | -8.27M | -6.40M | -7.14M | -7.70M | -10.90M | -12.35M | -13.24M | -10.34M | -12.30M | -11.80M | -13.19M | -17.80M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.49 | -0.34 | -0.24 | -0.14 | -0.12 | -0.06 | -0.07 | -0.08 | -0.11 | -0.12 | -0.13 | -0.09 | -0.09 | -0.08 | -0.09 | -0.11 |
| R&D Expense | 2.36M | 3.44M | 3.75M | 3.34M | 5.53M | 5.65M | 6.02M | 4.92M | 4.83M | 5.59M | 6.50M | 4.72M | 4.64M | 5.10M | 5.77M | 5.00M | 5.84M | 6.32M | 8.80M | 10.02M | 11.22M | 7.81M | 9.39M | 10.09M | 9.94M | 15.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -18.41M | -26.64M | -32.49M | -32.48M | -29.91M | -33.92M | -51.52M | -49.33M |
| Net Income | -20.55M | -26.05M | -32.76M | -33.94M | -29.15M | -29.07M | -47.91M | -42.76M |
| Diluted EPS | - | - | - | -1.49 | -0.45 | -0.29 | -0.47 | -0.32 |
| R&D Expense | 14.07M | 19.34M | 22.33M | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.53M | 60.00M | 47.13M | 38.48M | 123.02M | 89.40M | 110.90M | 193.44M |
| Total Equity | -84.43M | -109.49M | 54.55M | 27.28M | 17.07M | 107.46M | 82.55M | 99.64M | 183.24M |
| Cash & Equivalents | - | 7.20M | 57.31M | 45.00M | 36.83M | 12.59M | 32.40M | 34.10M | 18.91M |
| Total Liabilities | - | - | - | 19.85M | 21.40M | 15.56M | 6.86M | 11.26M | 10.20M |
| Current Liabilities | - | 2.68M | 5.20M | 5.55M | 12.72M | 13.40M | 5.82M | 10.51M | 9.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.29M | -23.09M | -29.00M | -28.95M | -28.18M | -31.71M | -38.26M | -42.09M |
| Investing Cash Flow | -158.00K | -9.00K | -32.00K | - | -107.37M | 59.43M | -21.53M | -94.11M |
| Financing Cash Flow | 3.63M | 73.21M | 16.72M | 20.77M | 111.31M | -7.91M | 61.48M | 121.01M |
| Capital Expenditure | -158.00K | -9.00K | -32.00K | - | -159.00K | -137.00K | -35.00K | -12.00K |
| Free Cash Flow | -18.45M | -23.10M | -29.03M | - | -28.33M | -31.85M | -38.29M | -42.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 18.8% | -47.8% | -120.1% | -198.8% | -27.1% | -35.2% | -48.1% | -23.3% |
| ROCE % | -234.5% | -48.6% | -78.1% | -126.1% | -27.3% | -40.6% | -51.3% | -26.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | NEA Management Company, LLC | 9.28% | 13.22M | $174.40M |
| 2 | FMR, LLC | 8.82% | 12.56M | $165.70M |
| 3 | Blackrock Inc. | 7.83% | 11.16M | $147.13M |
| 4 | Frazier Life Sciences Management, L.P. | 6.98% | 9.94M | $131.10M |
| 5 | Wellington Management Group, LLP | 3.99% | 5.68M | $74.98M |
| 6 | Vanguard Capital Management LLC | 3.88% | 5.53M | $72.95M |
| 7 | Vivo Capital, LLC | 3.58% | 5.09M | $67.20M |
| 8 | Woodline Partners LP | 2.86% | 4.08M | $53.83M |
| 9 | Vestal Point Capital, LP | 2.18% | 3.10M | $40.89M |
| 10 | MPM Bioimpact LLC | 2.16% | 3.07M | $40.54M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRVI
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNX20xZ1NzYzBkSGJpdGU2TV9JRHd1UVZUbjZ1aHFsZC1KcklyWmE2VzhlWHdFaHRJUGJqU3NiT1UtVll3VVpYb19qdmpXNm5iV0NZV2FUb0x2T2hobVdPLVJFZ3VIbXpoYjBTLUl3ZENvOXhER0RBcnJGQk01c2JNY2szWFNuRk42b1lzMm…
TRVI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE04OGZGcTVjVzI2UXl6ek9NNWtDVUE5dzlySzFnZnRwU01PSW5EZHIzZ1czOXhCczdCS2ExLV9Tb0MxdFRDR0dPTjFhZUlMNjkxeDdtRDlZYnl3ZUxpQjY3ZTc2WWdFRUVHcm5tbkdnbjdEQmNZUlhCLWR3?oc=5" target="_blank">TRV…
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPanVmRG1rMnAwQXFwRmRlenpwdUFSaHdob1Q2YnozLUJvUjlEWW1LcG9SNVRIY3o4eWdNazNJYkZuVUc4cmlmTjlPa21mOU91ZzVnWGp0dUs1S3JOcUd4MnA2ejJNZUFDZU0zaW1TMmVHUDRyNE5aVklFaEMtMnRsX1JkeTliV0t6ZzdXY3…
TRVI Nov 2026 11.000 call (TRVI261120C00011000) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBDVl9uZGlLejJkVFdVbFA1WTJ0TlFHUHdSd3lQbjRtMExzV2VEQ3RoUmxBRHM3a2VkRFZmeTJnTV83ak52Z05EOXZoWnNGYzdIcEdnNGMyOTJwN3pyVzlpTjFFaFM3MHQ1M1FCY2l3?oc=5" target="_blank">TRVI Nov 2026 11.00…
Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update - Investing.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxON0htQ1F3dzF5cExWUFZzeDFHQkFXV1VNVWhBNE5qSDdPc3dfcm9VYjVLQnFQNHFsVG1YczJ4N2ZGM2p1Q0NOTlBKU01xNmdlOF90MFdpSFBaTWwzUnRPT2gyQ0VrZWNtTHhLdmJUQWVJWXVIcmlXZ3FyeWZQVjFFclBDOEp3SGhZc2prQ2…
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPdmRWYlQ2b1pqa0tNV0RvYS05RFB4TXh6MVlVcHlaM01oeURDWU9GcnJ4djUyekhKUWtUUXFPOXE1QTJZLTRhQXVlRFd4MWFNWUUwUFBrSzZEMGFVY09PZldnbFcwc2RvWmtVSUdNZjJPcWM2RGZfNUdhbExSdHRfM1BSYm8zSHFIZ1NYLV…
TRVI — Frequently Asked Questions
What is the current share price of Trevi Therapeutics, Inc. (TRVI)?
As of 2026-10-23 16:27 PDT, Trevi Therapeutics, Inc. (TRVI) trades at $12.61 on NasdaqGM. Its 52-week range is $7.01 to $19.50.
What is the market capitalisation of TRVI?
Trevi Therapeutics, Inc. (TRVI) has a market capitalisation of $1.80B on NasdaqGM.
What is the P/E ratio of TRVI?
TRVI trades at a trailing price-to-earnings (P/E) ratio of -36.03. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.62.
What is the return on equity (ROE) of TRVI?
TRVI has a return on equity (ROE) of -19.66%. Its return on capital employed (ROCE) is -26.85%.
Is TRVI a good stock to buy?
This page provides a data-driven analysis of Trevi Therapeutics, Inc. (TRVI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.